增强的向药物输送系统来控制贪和药物封装使用E2纳米和SpyTag/SpyCatcher
Dohee Ahn1, Sun Hee Park2,3, Yeong Geun Lee1,3
1Department of Biopharmaceutical Convergence, Sungkyunkwan University, Suwon 16419, Republic of Korea.
ACS biomaterials science & engineering
|April 10, 2025
概括
工程化蛋白质纳米通过精确向HER2阳性癌细胞,提供强效的抗癌药物. 这种先进的药物输送系统增强了结合力,并表现出强大的细胞毒性,为下一代癌症疗法铺平了道路.
科学领域:
- 生物技术是生物技术.
- 纳米技术纳米技术
- 在瘤学瘤学.
背景情况:
- 抗体-药物结合剂在携带疏水性有效载荷方面面临限制.
- 蛋白质纳米为向药物输送提供了优势,包括精确的组装和生物相容性.
研究的目的:
- 开发工程E2蛋白纳米,用于水性抗癌药物的向输送.
- 使用SpyTag/SpyCatcher系统在纳米上控制抗HER2单链可变片段 (scFv) 的显示价值.
- 评估scFv价值对HER2结合率和药物装载纳米的细胞毒性的影响.
主要方法:
- 工程E2纳米与使用SpyTag/SpyCatcher结合控制价值的抗HER2 scFv功能化.
- 通过maleimide化学,引入了氨酸残留物以与单甲基奥里斯塔丁E (MMAE) 结合.
- 在HER2阳性 (SKBR3,BT-474) 和HER2阴性 (MDA-MB-231) 细胞系中评估了细胞毒性.
主要成果:
- 增加的抗HER2 scFv 价值增强了 HER2 结合亲和力,通过狂热效应.
- 在E2纳米中实现了MMAE的有效加载.
- 与MMAE结合的纳米细胞表现出强大的亚纳米细胞毒性对HER2阳性细胞,同时不影响HER2阴性细胞.
结论:
- 在增强HER2向和结合性方面,scFv的价值是至关重要的.
- E2蛋白纳米代表了针对特定和强大的向癌症治疗的有希望的平台.
- 这些纳米的模块化设计和pH敏感解离支持未来的精准医学策略.
更多相关视频
相关概念视频
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...